Oxford Biomedica Revenue and Competitors
Estimated Revenue & Valuation
- Oxford Biomedica's estimated annual revenue is currently $132.5M per year.
- Oxford Biomedica's estimated revenue per employee is $155,000
Employee Data
- Oxford Biomedica has 855 Employees.
- Oxford Biomedica grew their employee count by -12% last year.
Oxford Biomedica's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CIO and Chief Staff | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | QC Officer | Reveal Email/Phone |
4 | QC Officer IV | Reveal Email/Phone |
5 | Head Digital Delivery | Reveal Email/Phone |
6 | QA Officer | Reveal Email/Phone |
7 | Head Environment Health and Safety and Business Responsibility | Reveal Email/Phone |
8 | Head Translational Medicine | Reveal Email/Phone |
9 | VP, Process Development | Reveal Email/Phone |
10 | VP, Corporate Affairs and Investor Relations | Reveal Email/Phone |
Oxford Biomedica Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is Oxford Biomedica?
Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. We have built a sector-leading lentiviral vector delivery platform, called LentiVector®, which we use to develop in vivo and ex vivo products both in-house and with partners. We have created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We also have a number of partnerships, including with Novartis, Sanofi, GSK and Orchard Therapeutics, where we have long-term economic interests in other potential gene and cell therapy products. OXB is based across four locations in Oxfordshire, UK.
keywords:N/A
N/A
Total Funding
855
Number of Employees
$132.5M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oxford Biomedica News
Oxford BioMedica acquired an 80 per cent stake in Massachusetts-based Homology Medicines for £97mn in January, funded partly through debt. The...
Oxford, UK 20 April 2022: Oxford Biomedica plc (LSE: OXB), (Oxford Biomedica or the Group), a leading cell and gene therapy group,...
Oxford Biomedica Plc: The vaccine manufacturer expects less revenue in this year compared to 2021 due to a pause in vaccine manufacturing...
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK - 19 October 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, today announces that ...
Serum Life Sciences, a unit of SII, will pick up a 3.9% stake in Oxford Biomedica as part of the deal Vaccine maker Serum Institute of India (SII) will invest £50 million ($68 million) in OxfordBiomedica to help fund the development of a plant that manufactures Covid-19 shots, the British compa ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $119.7M | 855 | -8% | N/A |
#2 | $35M | 855 | 2% | N/A |
#3 | $365.9M | 857 | -44% | N/A |
#4 | $171.8M | 858 | -6% | $16M |
#5 | $192.2M | 858 | N/A | N/A |